文献速递免疫规划

HPV18 E6特异性T细胞反应的特征描述及HPV18 E6表达肿瘤模型的建立

Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.
PubMed 文献 · Vaccine · 2017-06-07

研究以原型DNA疫苗pcDNA3-HPV18-E6肌内注射后电穿孔免疫naïve C57BL/6小鼠,用流式细胞术分析E6特异性CD8+ T细胞反应并鉴定表位MHC限制元件;建立HPV18-E6表达肿瘤细胞系TC-1/HPV18-E6,观察到疫苗显著抑制肿瘤生长,抗体清除实验显示CD4+和CD8+ T细胞均为抗肿瘤免疫所必需。

要点

  • pcDNA3-HPV18-E6疫苗接种后诱导强健的HPV18-E6aa67-75肽特异性CD8+ T细胞反应
  • 该表位主要受H-2Kb限制,也可被HLA-A*0201弱递呈
  • 疫苗显著抑制TC-1/HPV18-E6肿瘤细胞生长,CD4+和CD8+ T细胞均必需

核心结论

  • HPV18-E6特异性T细胞反应的特征描述及HPV18-E6表达肿瘤细胞系的建立为HPV18-E6靶向免疫治疗的进一步开发提供了基础设施。

研究设计与样本

  • 研究用原型DNA疫苗pcDNA3-HPV18-E6经肌内注射后电穿孔免疫naïve C57BL/6小鼠
  • 用流式细胞术分析E6特异性CD8+ T细胞反应并鉴定表位MHC限制元件
  • 建立HPV18-E6表达肿瘤细胞系TC-1/HPV18-E6以研究E6特异性免疫介导的抗肿瘤效应

主要发现

  • 接种pcDNA3-HPV18-E6后观察到强健的HPV18-E6aa67-75肽特异性CD8+ T细胞反应
  • 该表位主要受H-2Kb限制,但也如既往报道被HLA-A*0201弱递呈
  • 接种pcDNA3-HPV18-E6显著抑制小鼠体内HPV18-E6表达肿瘤细胞TC-1/HPV18-E6的生长
  • 抗体清除实验显示CD4+和CD8+ T细胞均为所观察到的抗肿瘤免疫所必需

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human papillomavirus (HPV) has been identified as the primary etiologic factor of cervical cancer, and subsets of anogenital and oropharyngeal cancers. HPV18 is the second most prevalent high-risk HPV type after HPV16. Furthermore, HPV18 is responsible for approximately 12% of cervical squamous cell carcinoma and 37% of cervical adenocarcinoma cases worldwide. In this study, we aimed to characterize the HPV18-E6-specific epitope and establish an HPV18 animal tumor model to evaluate the E6-specific immune response induced by our DNA vaccine. We vaccinated naïve C57BL/6 mice with a prototype DNA vaccine, pcDNA3-HPV18-E6, via intramuscular injection followed by electroporation, and analyzed the E6-specific CD8+ T cell responses by flow cytometry using a reported T cell epitope. We then characterized the MHC restriction element for the characterized HPV18-E6 epitope. Additionally, we generated an HPV18-E6-expressing tumor cell line to study the antitumor effect mediated by E6-specific immunity. We observed a robust HPV18-E6aa67-75 peptide-specific CD8+ T cell response after vaccination with pcDNA3-HPV18-E6. Further characterization demonstrated that this epitope was mainly restricted by H-2Kb, but was also weakly presented by HLA-A∗0201, as previously reported. We observed that vaccination with pcDNA3-HPV18-E6 significantly inhibited the growth of HPV18-E6-expressing tumor cells, TC-1/HPV18-E6, in mice. An antibody depletion study demonstrated that both CD4+ and CD8+ T cells are necessary for the observed antitumor immunity. The characterization of HPV18-E6-specific T cell responses and the establishment of HPV18-E6-expressing tumor cell line provide infrastructures for further development of HPV18-E6 targeted immunotherapy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ma Y, Yang A, Peng S, et al. Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model. Vaccine. 2017. PMID: 28599791. doi:10.1016/j.vaccine.2017.05.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。